공고 • Jul 10
Ocumetics Technology Corp. Reports Positive Six-Month Results and Advances Next-Generation Ocumetics Lens to Group Two Clinical Surgeries Ocumetics Technology Corp. reported positive six-month results from its First-in-Human clinical study, supporting advancement to Group Two clinical surgeries. Positive six-month clinical data have supported progression to Group Two surgeries. Manufacturing of the redesigned Ocumetics Lens has commenced, regulatory milestones have been achieved, and strategic engagement with leading global ophthalmic companies continue to build momentum. Six-month follow-up data from Group One patients enrolled in the Company's First-in-Human clinical study continues to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered to be legally blind that is now qualified to drive. These positive clinical outcomes have provided the foundation necessary for Ocumetics to advance to the second group of its First-in-Human study (Group Two), representing another significant milestone toward commercialization. Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens. The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance while simplifying future commercial production. Expected benefits of the redesigned Ocumetics Lens include: Enhanced accommodative performance. Simplified lens architecture with one-piece design. Improved manufacturing consistency. Elimination of internal interface materials. No air, water or oil. Optimized surgical implantation characteristics. Improved compatibility with the redesigned lens delivery system. Greater scalability for commercial manufacturing. The Company intends to use this redesigned lens for the upcoming Group Two First-in-Human study surgeries. Manufacturing of the redesigned Ocumetics Lens has commenced with the Company's German manufacturing partner, Amiplant GmbH. Upcoming activities include finalization of manufacturing, product verification, sterilization, product packaging and release of clinical inventory ahead of the planned Third Quarter 2026 clinical surgeries. Ocumetics has successfully completed all regulatory requirements necessary to proceed to Group Two patient enrollment. Upon completion of manufacturing and product release activities, patient recruitment and surgical scheduling will commence. Group Two patients are expected to receive the redesigned Ocumetics Lens delivered with the Company's updated lens delivery system. The Ocumetics Lens and the lens delivery system each incorporate improvements developed through previous preclinical work and feedback from the Group One First-in-Human surgery experience. 공고 • Jul 08
Ocumetics Technology Corp. announced that it expects to receive CAD 2 million in funding Ocumetics Technology Corp .announced to issue up to 5,000,000 units of the Corporation at a price of CAD 0.40 per Unit for gross proceeds of up to CAD 2,000,000. There will be no minimum subscription level for the Offering. Each Unit will consist of one common share in the share capital of the Corporation and one common share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.50 for a period of three years from the date of issuance of the Warrant. The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least CAD 0.75 per Common Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be accelerated by the Corporation to a date that is not less than 30 days after the date that notice of such acceleration is provided to the Warrant holders by way of a press release. The Offering may include finder’s fees commissions payable in cash and/or securities and is subject to approval of the TSX Venture Exchange. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. Insiders may participate in the Offering. Any participation by insiders in the Offering will constitute a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions but is expected to be exempt from the formal valuation and minority shareholder
approval requirements of that instrument. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. 공고 • Apr 29
Ocumetics Technology Corp. announced that it expects to receive CAD 1.54 million in funding Ocumetics Technology Corp announced a private placement of up to 2,800,000 units of the Corporation at a price of CAD 0.55 per Unit for gross proceeds of up to CAD 1,540,000 on April 29, 2026. Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.75 for a period of three years from the date of issuance of the Warrant. The Corporation may pay finders fees to those who assist the Corporation in filling the Private Placement. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. 공고 • Dec 24
Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026 Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026. Recent Insider Transactions Derivative • Oct 07
CFO & Director exercised options to buy CA$2.1m worth of stock. On the 3rd of October, Roger Jewett exercised options to buy 2m shares at a strike price of around CA$0.12, costing a total of CA$219k. This transaction amounted to 648% of their direct individual holding at the time of the trade. Roger currently holds 1.89m shares (0.01506070670725128 of the company). Company insiders have collectively bought CA$422k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Aug 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.2m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-CA$4.0m). Earnings have declined by 24% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$65.9m market cap, or US$47.5m). 
